| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 89 | 2022 | 1061 | 5.100 |
Why?
|
| Carcinoma, Squamous Cell | 48 | 2019 | 1096 | 3.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 82 | 2024 | 2505 | 3.140 |
Why?
|
| Chemoradiotherapy | 15 | 2022 | 306 | 2.050 |
Why?
|
| Oropharyngeal Neoplasms | 10 | 2024 | 132 | 1.900 |
Why?
|
| Combined Modality Therapy | 80 | 2016 | 1704 | 1.660 |
Why?
|
| Fluorouracil | 58 | 2022 | 549 | 1.570 |
Why?
|
| Neoplasm Recurrence, Local | 26 | 2022 | 1350 | 1.390 |
Why?
|
| Mouth Neoplasms | 8 | 2018 | 198 | 1.340 |
Why?
|
| Hydroxyurea | 47 | 2022 | 239 | 1.290 |
Why?
|
| Radiotherapy Dosage | 35 | 2020 | 468 | 1.170 |
Why?
|
| Paclitaxel | 29 | 2024 | 474 | 1.070 |
Why?
|
| Carcinoma | 10 | 2022 | 438 | 1.030 |
Why?
|
| Aged | 110 | 2024 | 19230 | 0.910 |
Why?
|
| Re-Irradiation | 2 | 2022 | 15 | 0.910 |
Why?
|
| Nasopharyngeal Neoplasms | 5 | 2016 | 47 | 0.840 |
Why?
|
| Middle Aged | 112 | 2024 | 26103 | 0.800 |
Why?
|
| Disease-Free Survival | 32 | 2020 | 1168 | 0.800 |
Why?
|
| Neoplasms, Second Primary | 7 | 2011 | 260 | 0.790 |
Why?
|
| Radiation Dosage | 7 | 2020 | 230 | 0.760 |
Why?
|
| Neoplasm Staging | 36 | 2016 | 2000 | 0.760 |
Why?
|
| Cisplatin | 35 | 2022 | 598 | 0.750 |
Why?
|
| Induction Chemotherapy | 7 | 2022 | 152 | 0.730 |
Why?
|
| Alphapapillomavirus | 2 | 2021 | 46 | 0.720 |
Why?
|
| Insulin-Secreting Cells | 2 | 2014 | 406 | 0.710 |
Why?
|
| Adult | 98 | 2024 | 26784 | 0.700 |
Why?
|
| Papillomavirus Infections | 6 | 2024 | 264 | 0.680 |
Why?
|
| Male | 121 | 2024 | 42614 | 0.660 |
Why?
|
| Aged, 80 and over | 43 | 2020 | 6779 | 0.660 |
Why?
|
| Laryngeal Neoplasms | 8 | 2013 | 89 | 0.630 |
Why?
|
| Deglutition | 8 | 2020 | 77 | 0.620 |
Why?
|
| Female | 116 | 2024 | 46529 | 0.600 |
Why?
|
| Humans | 160 | 2024 | 89864 | 0.590 |
Why?
|
| Carboplatin | 15 | 2024 | 312 | 0.570 |
Why?
|
| Follow-Up Studies | 28 | 2019 | 3670 | 0.560 |
Why?
|
| Neoadjuvant Therapy | 7 | 2024 | 376 | 0.550 |
Why?
|
| Treatment Outcome | 45 | 2022 | 8264 | 0.540 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 17 | 2012 | 1130 | 0.540 |
Why?
|
| Survival Rate | 26 | 2019 | 1898 | 0.530 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 173 | 0.530 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2014 | 1180 | 0.510 |
Why?
|
| Papillomaviridae | 5 | 2022 | 156 | 0.510 |
Why?
|
| Survival Analysis | 21 | 2018 | 1497 | 0.500 |
Why?
|
| Lung Neoplasms | 21 | 2012 | 2368 | 0.490 |
Why?
|
| Radiotherapy, High-Energy | 3 | 2008 | 49 | 0.460 |
Why?
|
| Remission Induction | 16 | 2016 | 740 | 0.450 |
Why?
|
| Deglutition Disorders | 5 | 2011 | 119 | 0.450 |
Why?
|
| Quality of Life | 15 | 2020 | 1680 | 0.440 |
Why?
|
| Lymph Node Excision | 3 | 2013 | 220 | 0.440 |
Why?
|
| Mouth | 2 | 2018 | 48 | 0.420 |
Why?
|
| Prognosis | 26 | 2022 | 3789 | 0.390 |
Why?
|
| Organ Preservation | 2 | 2011 | 119 | 0.370 |
Why?
|
| Deoxycytidine | 4 | 2011 | 211 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2012 | 476 | 0.360 |
Why?
|
| Salvage Therapy | 6 | 2020 | 230 | 0.340 |
Why?
|
| Taxoids | 6 | 2014 | 124 | 0.340 |
Why?
|
| Adenocarcinoma | 5 | 2012 | 1183 | 0.330 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 1999 | 26 | 0.330 |
Why?
|
| Enteral Nutrition | 2 | 2020 | 105 | 0.310 |
Why?
|
| Esophageal Neoplasms | 6 | 2007 | 330 | 0.310 |
Why?
|
| Antineoplastic Agents, Phytogenic | 7 | 2012 | 274 | 0.290 |
Why?
|
| Antineoplastic Agents | 15 | 2012 | 2328 | 0.290 |
Why?
|
| Tongue | 1 | 2007 | 57 | 0.280 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2013 | 166 | 0.280 |
Why?
|
| Radiotherapy | 11 | 2011 | 332 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 4 | 2016 | 569 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2360 | 0.240 |
Why?
|
| Retrospective Studies | 26 | 2020 | 9185 | 0.240 |
Why?
|
| Neck Dissection | 6 | 2010 | 67 | 0.240 |
Why?
|
| Lymph Nodes | 5 | 2016 | 550 | 0.230 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2012 | 97 | 0.230 |
Why?
|
| Leucovorin | 14 | 2010 | 222 | 0.220 |
Why?
|
| Radiotherapy, Conformal | 4 | 2008 | 82 | 0.220 |
Why?
|
| Maximum Tolerated Dose | 7 | 2022 | 263 | 0.210 |
Why?
|
| Neoplasm Metastasis | 6 | 2011 | 1066 | 0.210 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2022 | 15 | 0.200 |
Why?
|
| Interferon-alpha | 11 | 2010 | 214 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2013 | 233 | 0.200 |
Why?
|
| Radiotherapy, Computer-Assisted | 3 | 2008 | 24 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2010 | 290 | 0.190 |
Why?
|
| DNA, Viral | 2 | 2022 | 263 | 0.190 |
Why?
|
| Radiation Tolerance | 6 | 1995 | 173 | 0.190 |
Why?
|
| Drug Administration Schedule | 14 | 2010 | 865 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2013 | 854 | 0.180 |
Why?
|
| Genes, p53 | 3 | 1996 | 109 | 0.180 |
Why?
|
| Ephrin-A2 | 1 | 2020 | 3 | 0.180 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 16 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 64 | 0.170 |
Why?
|
| Treatment Failure | 6 | 2010 | 278 | 0.170 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2011 | 80 | 0.170 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 425 | 0.170 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2012 | 185 | 0.170 |
Why?
|
| Cetuximab | 2 | 2019 | 115 | 0.170 |
Why?
|
| Prostatic Neoplasms | 6 | 2001 | 1735 | 0.160 |
Why?
|
| Tumor Virus Infections | 2 | 1996 | 83 | 0.150 |
Why?
|
| Vinblastine | 4 | 2002 | 100 | 0.150 |
Why?
|
| Quinazolines | 2 | 2010 | 212 | 0.150 |
Why?
|
| Disease Progression | 8 | 2011 | 1469 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2000 | 166 | 0.140 |
Why?
|
| Azacitidine | 3 | 1994 | 147 | 0.140 |
Why?
|
| Prospective Studies | 9 | 2022 | 4322 | 0.140 |
Why?
|
| Recombinant Proteins | 12 | 2010 | 1008 | 0.140 |
Why?
|
| Neutrons | 2 | 1995 | 57 | 0.130 |
Why?
|
| Probability | 5 | 2008 | 350 | 0.130 |
Why?
|
| Graft Survival | 1 | 2000 | 907 | 0.130 |
Why?
|
| Pneumonectomy | 3 | 2011 | 211 | 0.130 |
Why?
|
| Everolimus | 1 | 2016 | 35 | 0.130 |
Why?
|
| Incidence | 8 | 2016 | 1600 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2020 | 2676 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 451 | 0.130 |
Why?
|
| Meningioma | 1 | 1996 | 62 | 0.130 |
Why?
|
| Photons | 1 | 1995 | 47 | 0.120 |
Why?
|
| Osteoradionecrosis | 3 | 2010 | 18 | 0.120 |
Why?
|
| ErbB Receptors | 3 | 2020 | 498 | 0.120 |
Why?
|
| Confidence Intervals | 4 | 2008 | 221 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 168 | 0.120 |
Why?
|
| Decision Making | 1 | 2020 | 669 | 0.120 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 58 | 0.120 |
Why?
|
| Cell Dedifferentiation | 1 | 2014 | 8 | 0.120 |
Why?
|
| Adolescent | 14 | 2022 | 9327 | 0.120 |
Why?
|
| Hypopharyngeal Neoplasms | 2 | 2013 | 15 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1452 | 0.120 |
Why?
|
| Expert Testimony | 1 | 2014 | 34 | 0.120 |
Why?
|
| Preventive Medicine | 1 | 2014 | 18 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2000 | 1076 | 0.110 |
Why?
|
| Plaque, Amyloid | 1 | 2014 | 59 | 0.110 |
Why?
|
| Camptothecin | 4 | 2010 | 195 | 0.110 |
Why?
|
| Clinical Trials as Topic | 6 | 2004 | 1134 | 0.110 |
Why?
|
| Population Groups | 1 | 2013 | 41 | 0.110 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 86 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2014 | 3403 | 0.110 |
Why?
|
| Tongue Neoplasms | 2 | 2010 | 52 | 0.110 |
Why?
|
| Feasibility Studies | 6 | 2022 | 785 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2014 | 115 | 0.110 |
Why?
|
| Platinum | 2 | 2012 | 64 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2000 | 855 | 0.110 |
Why?
|
| Cell Death | 1 | 2014 | 261 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 1929 | 0.110 |
Why?
|
| Risk Assessment | 6 | 2016 | 2324 | 0.110 |
Why?
|
| Cohort Studies | 9 | 2009 | 2886 | 0.100 |
Why?
|
| Biological Assay | 1 | 2012 | 79 | 0.100 |
Why?
|
| Research Design | 3 | 2013 | 591 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
| Administration, Oral | 5 | 2001 | 666 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 1992 | 133 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2011 | 152 | 0.100 |
Why?
|
| Mutation | 4 | 2022 | 4164 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2014 | 458 | 0.090 |
Why?
|
| Glutamates | 2 | 2011 | 88 | 0.090 |
Why?
|
| Speech | 1 | 2010 | 85 | 0.090 |
Why?
|
| Guanine | 2 | 2011 | 207 | 0.090 |
Why?
|
| Autophagy | 1 | 2012 | 159 | 0.090 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1989 | 6 | 0.090 |
Why?
|
| Time Factors | 9 | 2012 | 5357 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 521 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1054 | 0.080 |
Why?
|
| DNA | 2 | 2012 | 1311 | 0.080 |
Why?
|
| Fluoroscopy | 2 | 2007 | 127 | 0.080 |
Why?
|
| Risk Factors | 8 | 2013 | 5548 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2008 | 682 | 0.080 |
Why?
|
| Uracil | 2 | 1999 | 55 | 0.080 |
Why?
|
| Vocal Cords | 1 | 1988 | 28 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2006 | 899 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 981 | 0.080 |
Why?
|
| Video Recording | 2 | 2007 | 203 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2011 | 287 | 0.080 |
Why?
|
| Pneumonia, Aspiration | 1 | 2007 | 19 | 0.070 |
Why?
|
| Infusions, Intravenous | 5 | 2002 | 416 | 0.070 |
Why?
|
| Palliative Care | 2 | 2004 | 264 | 0.070 |
Why?
|
| Surgical Flaps | 2 | 2008 | 250 | 0.070 |
Why?
|
| Triazines | 1 | 2007 | 54 | 0.070 |
Why?
|
| Survival | 2 | 2003 | 21 | 0.070 |
Why?
|
| Thoracic Neoplasms | 2 | 1998 | 66 | 0.070 |
Why?
|
| Retreatment | 3 | 2012 | 107 | 0.070 |
Why?
|
| Biopsy | 2 | 2009 | 1184 | 0.070 |
Why?
|
| Young Adult | 2 | 2022 | 6389 | 0.060 |
Why?
|
| Mandibular Diseases | 1 | 2005 | 16 | 0.060 |
Why?
|
| Rad51 Recombinase | 1 | 2006 | 81 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 1255 | 0.060 |
Why?
|
| Smoking | 5 | 2014 | 625 | 0.060 |
Why?
|
| Organoplatinum Compounds | 2 | 2004 | 94 | 0.060 |
Why?
|
| CHO Cells | 3 | 1994 | 188 | 0.060 |
Why?
|
| Bevacizumab | 3 | 2011 | 268 | 0.060 |
Why?
|
| United States | 2 | 2016 | 7094 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 586 | 0.060 |
Why?
|
| Radiography | 4 | 2014 | 808 | 0.060 |
Why?
|
| Etoposide | 2 | 2008 | 206 | 0.060 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2003 | 15 | 0.060 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 30 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2003 | 848 | 0.050 |
Why?
|
| Travel | 1 | 2003 | 72 | 0.050 |
Why?
|
| Lymphatic Metastasis | 4 | 2012 | 495 | 0.050 |
Why?
|
| DNA Repair | 4 | 2006 | 363 | 0.050 |
Why?
|
| Creatinine | 2 | 2001 | 294 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 129 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 56 | 0.050 |
Why?
|
| Regression Analysis | 3 | 1999 | 591 | 0.050 |
Why?
|
| Patient Selection | 2 | 2003 | 682 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 140 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2009 | 189 | 0.050 |
Why?
|
| Area Under Curve | 3 | 2008 | 338 | 0.050 |
Why?
|
| Attitude to Health | 2 | 2000 | 222 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 147 | 0.050 |
Why?
|
| Child | 1 | 2012 | 7233 | 0.050 |
Why?
|
| Cricetinae | 5 | 1994 | 558 | 0.050 |
Why?
|
| Neoplasms | 3 | 2008 | 3062 | 0.050 |
Why?
|
| Receptor, EphA2 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 12 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 20 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2020 | 23 | 0.040 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2000 | 4 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 2001 | 66 | 0.040 |
Why?
|
| Histocompatibility | 1 | 2000 | 65 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 952 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2011 | 983 | 0.040 |
Why?
|
| Sex Factors | 2 | 2000 | 1074 | 0.040 |
Why?
|
| Cause of Death | 2 | 2004 | 269 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2003 | 384 | 0.040 |
Why?
|
| Videotape Recording | 1 | 1999 | 48 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 1394 | 0.040 |
Why?
|
| Cell Survival | 5 | 1994 | 983 | 0.040 |
Why?
|
| Pemetrexed | 2 | 2011 | 76 | 0.040 |
Why?
|
| Tegafur | 1 | 1998 | 17 | 0.040 |
Why?
|
| DNA Damage | 2 | 1991 | 373 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1999 | 112 | 0.040 |
Why?
|
| Pharynx | 1 | 2018 | 44 | 0.040 |
Why?
|
| Neck | 1 | 1999 | 104 | 0.040 |
Why?
|
| Head | 1 | 1999 | 137 | 0.040 |
Why?
|
| Jaw Diseases | 1 | 1998 | 8 | 0.040 |
Why?
|
| Chicago | 5 | 2003 | 1431 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 846 | 0.040 |
Why?
|
| Drug Evaluation | 3 | 1992 | 137 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 305 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 474 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 182 | 0.030 |
Why?
|
| Age Factors | 3 | 2013 | 1880 | 0.030 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 1996 | 20 | 0.030 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 1996 | 14 | 0.030 |
Why?
|
| Alcohol Drinking | 3 | 2011 | 273 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2020 | 413 | 0.030 |
Why?
|
| Drug Tolerance | 2 | 1996 | 64 | 0.030 |
Why?
|
| Skull Neoplasms | 2 | 1995 | 30 | 0.030 |
Why?
|
| Radiation Injuries | 4 | 2003 | 161 | 0.030 |
Why?
|
| Rectum | 1 | 1995 | 148 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1283 | 0.030 |
Why?
|
| X-Rays | 2 | 1991 | 137 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2000 | 693 | 0.030 |
Why?
|
| Penile Neoplasms | 1 | 1994 | 17 | 0.030 |
Why?
|
| Bone Marrow | 4 | 1998 | 443 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1542 | 0.030 |
Why?
|
| Esophagitis | 3 | 1998 | 43 | 0.030 |
Why?
|
| Biomarkers | 1 | 2000 | 1774 | 0.030 |
Why?
|
| Illinois | 2 | 2007 | 485 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2013 | 70 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2006 | 871 | 0.030 |
Why?
|
| Methods | 1 | 1992 | 151 | 0.020 |
Why?
|
| Mercaptoethylamines | 1 | 1992 | 52 | 0.020 |
Why?
|
| Neutropenia | 3 | 1998 | 214 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 1996 | 603 | 0.020 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 46 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 1991 | 321 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 19 | 0.020 |
Why?
|
| Free Radicals | 1 | 1991 | 71 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1992 | 98 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 36 | 0.020 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 1991 | 12 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2006 | 1864 | 0.020 |
Why?
|
| Animals | 8 | 2012 | 27516 | 0.020 |
Why?
|
| Laparoscopy | 2 | 1996 | 777 | 0.020 |
Why?
|
| Temporal Bone | 1 | 1991 | 68 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 1996 | 1858 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1994 | 366 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 372 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 301 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 1990 | 181 | 0.020 |
Why?
|
| Surveys and Questionnaires | 3 | 2006 | 2649 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 88 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 135 | 0.020 |
Why?
|
| Models, Biological | 2 | 2012 | 1765 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 352 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2007 | 30 | 0.020 |
Why?
|
| Activities of Daily Living | 2 | 2000 | 205 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1990 | 296 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1988 | 148 | 0.020 |
Why?
|
| Sarcoma | 1 | 1988 | 219 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 776 | 0.020 |
Why?
|
| Cell Line | 4 | 1992 | 2495 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 293 | 0.020 |
Why?
|
| Wound Healing | 2 | 2000 | 361 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2003 | 840 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 47 | 0.010 |
Why?
|
| Diet | 2 | 1999 | 444 | 0.010 |
Why?
|
| Radiometry | 1 | 2004 | 58 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1799 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 231 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 395 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 196 | 0.010 |
Why?
|
| Bias | 1 | 2003 | 135 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2003 | 90 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1995 | 1048 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2003 | 171 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 106 | 0.010 |
Why?
|
| Methotrexate | 2 | 1992 | 243 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 166 | 0.010 |
Why?
|
| Bleomycin | 2 | 1992 | 103 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 803 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 79 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 21 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 345 | 0.010 |
Why?
|
| Speech Intelligibility | 1 | 2000 | 10 | 0.010 |
Why?
|
| Xerostomia | 1 | 2000 | 10 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 952 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 2000 | 43 | 0.010 |
Why?
|
| Voice | 1 | 2000 | 20 | 0.010 |
Why?
|
| Taste | 1 | 2000 | 28 | 0.010 |
Why?
|
| Esthetics | 1 | 2000 | 45 | 0.010 |
Why?
|
| Spirometry | 1 | 2000 | 67 | 0.010 |
Why?
|
| Physical Phenomena | 1 | 1999 | 7 | 0.010 |
Why?
|
| Immobilization | 1 | 1999 | 21 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2000 | 125 | 0.010 |
Why?
|
| Tretinoin | 1 | 2000 | 128 | 0.010 |
Why?
|
| Physics | 1 | 1999 | 21 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2003 | 2301 | 0.010 |
Why?
|
| Demography | 1 | 2000 | 183 | 0.010 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 1999 | 28 | 0.010 |
Why?
|
| Mastication | 1 | 2000 | 78 | 0.010 |
Why?
|
| Levoleucovorin | 1 | 1998 | 3 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 1729 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 387 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1992 | 3021 | 0.010 |
Why?
|
| Esophagus | 1 | 1998 | 107 | 0.010 |
Why?
|
| Pain | 1 | 2000 | 399 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 77 | 0.010 |
Why?
|
| Speech Disorders | 1 | 1996 | 19 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1996 | 13 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1996 | 102 | 0.010 |
Why?
|
| Body Image | 1 | 1996 | 79 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 644 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1996 | 171 | 0.010 |
Why?
|
| Cutaneous Fistula | 1 | 1995 | 11 | 0.010 |
Why?
|
| Esophagogastric Junction | 1 | 1995 | 34 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1996 | 177 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1994 | 20 | 0.010 |
Why?
|
| Filgrastim | 1 | 1994 | 57 | 0.010 |
Why?
|
| Contrast Media | 1 | 2000 | 1084 | 0.010 |
Why?
|
| Lymphatic Irradiation | 1 | 1994 | 7 | 0.010 |
Why?
|
| Oncogenes | 1 | 1995 | 97 | 0.010 |
Why?
|
| Feeding and Eating Disorders | 1 | 1996 | 182 | 0.010 |
Why?
|
| Arteries | 1 | 1995 | 179 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 231 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 187 | 0.010 |
Why?
|
| Pelvis | 1 | 1994 | 96 | 0.010 |
Why?
|
| S Phase | 1 | 1993 | 63 | 0.010 |
Why?
|
| G1 Phase | 1 | 1993 | 65 | 0.010 |
Why?
|
| Depression | 1 | 1997 | 513 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 1992 | 25 | 0.010 |
Why?
|
| Emotions | 1 | 1996 | 353 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 171 | 0.010 |
Why?
|
| Stomatitis | 1 | 1992 | 30 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 227 | 0.010 |
Why?
|
| Triacetoneamine-N-Oxyl | 1 | 1991 | 3 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1993 | 171 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 1994 | 338 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 1994 | 256 | 0.010 |
Why?
|
| Astatine | 1 | 1990 | 3 | 0.010 |
Why?
|
| Algorithms | 1 | 1999 | 1908 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1990 | 101 | 0.010 |
Why?
|
| Cytokines | 1 | 1995 | 811 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1991 | 232 | 0.010 |
Why?
|
| Yttrium Radioisotopes | 1 | 1990 | 58 | 0.010 |
Why?
|
| Length of Stay | 1 | 1994 | 745 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1990 | 134 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 919 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1991 | 388 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1990 | 193 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1991 | 318 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1990 | 156 | 0.010 |
Why?
|
| Pyrimidines | 1 | 1992 | 371 | 0.010 |
Why?
|
| Kinetics | 1 | 1991 | 1534 | 0.000 |
Why?
|
| Base Sequence | 1 | 1992 | 2329 | 0.000 |
Why?
|
| Transfection | 1 | 1990 | 909 | 0.000 |
Why?
|
| Sarcoma, Ewing | 1 | 1988 | 44 | 0.000 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1988 | 128 | 0.000 |
Why?
|
| Osteosarcoma | 1 | 1988 | 161 | 0.000 |
Why?
|
| Recurrence | 1 | 1990 | 1144 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1988 | 996 | 0.000 |
Why?
|